Drug Profile
Velufenacin - Dong-A ST
Alternative Names: DA-8010Latest Information Update: 09 Feb 2024
Price :
$50
*
At a glance
- Originator Dong-A ST
- Class Urologics
- Mechanism of Action Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Overactive bladder
Highest Development Phases
- Phase III Overactive bladder
Most Recent Events
- 05 Dec 2023 Dong-A ST completes a phase I drug-drug interaction trial in Healthy volunteers in South Korea (NCT05992428)
- 17 Nov 2023 Dong-A ST completes the phase I trial in Overactive bladder (In volunteers) in South Korea (NCT05991401)
- 22 Aug 2023 Dong-A ST initiates a phase I drug-drug interaction trial in Healthy volunteers in South Korea (NCT05992428)